Eli Lilly and Company & Pfizer
12 shared events · Importance 3 · Last updated Sep 04, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
Eli Lilly and Company: Lilly leads GLP-1 sales in China and runs prominent awareness campaigns, though it paused its India campaign. Its Mounjaro is gaining patient demand.
Pfizer: Pfizer entered the Chinese market with Xianweiying and partners with gyms for promotions. It is a newer entrant seeking market share.
Aug 24, 2026 · 6 articles
Domestic
Eli Lilly and Company: Eli Lilly was among the earlier drugmakers that agreed to MFN pricing, contributing to the administration's drug pricing push.
Pfizer: Pfizer was among the earlier 17 drugmakers that signed MFN deals, setting a precedent. The new agreements expand the framework to more companies.
Aug 18, 2026 · 37 articles
Business
Eli Lilly and Company: Central subject of the event: shares fell about 7-8% over the month on pricing and IPR&D charges despite strong Q2 beats and raised 2026 guidance. Citi's Street-high $1,600 target frames the selloff as overdone, leaving the stock as the widest analyst-implied upside in its pharma peer group.
Pfizer: Peer with only about 4.1% implied upside and Hold-skewed ratings, underscoring how Lilly stands out on analyst-implied returns within pharma.
Sep 14, 2026 · 6 articles
Business
Eli Lilly and Company: Eli Lilly's Olumiant is a competitor JAK inhibitor for alopecia areata; positive bempikibart data may increase competition.
Pfizer: Pfizer's Litfulo is a competitor JAK inhibitor; positive bempikibart data may affect its market position.
Jul 13, 2026 · 6 articles
Regulatory
Eli Lilly and Company: Eli Lilly supported Gilead's appeal, benefiting from the ruling that protects drugmakers from duty-to-innovate claims.
Pfizer: Pfizer supported Gilead's appeal, gaining from the precedent that protects pharmaceutical innovation.
Aug 03, 2026 · 6 articles
Business
Eli Lilly and Company: Eli Lilly is mentioned as having a chief AI officer, but not directly impacted.
Pfizer: Pfizer is mentioned as having a chief AI officer, but not directly impacted.
Aug 11, 2026 · 7 articles
Business
Eli Lilly and Company: Eli Lilly and Company is a leading pharmaceutical company with strong balance sheets, enabling it to be a major acquirer in the current M&A wave. It is also facing patent expirations on some of its blockbuster drugs.
May 01, 2026 · 6 articles
Regulatory
Pfizer: Pfizer had previously struck a deal with the administration to rein in prices and expects United States — Medicaid discounts to result in price and margin compression next year.
Dec 19, 2025 · 7 articles
Business
Pfizer: Pfizer India partnered with Cipla to expand the reach of its medicines across India, while continuing to manufacture and supply the four brands involved in the agreement.
Dec 19, 2025 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Eli Lilly and Company and Pfizer interact across events, view sentiment trends, and discover connected entities.
Open Dashboard